Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Users share experiences and support, mentioning that many people face hair thinning.
The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.
People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.
A 25-year-old is experiencing chronic telogen effluvium (TE) and androgenetic alopecia (AGA) after surgery, using finasteride, red light therapy, and supplements, and considering oral minoxidil despite heart concerns. They are unsure whether to start minoxidil before or after an upcoming surgery, which may trigger another hair shed.
The conversation discusses hair loss concerns, specifically traction alopecia and hair loss from acne. It mentions that sleeping on one side is unlikely to cause traction alopecia.
CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.
The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.
A person feels intense shame and self-hatred due to baldness and poor self-image, affecting their confidence and social interactions. Suggestions include therapy, exercise, braces, hair transplants, and using finasteride.
The user experienced hair shedding in late summer after starting finasteride in December 2023, with regrowth by February. They are concerned about shedding again and question if finasteride is losing effectiveness.
The user experienced significant hair shedding despite long-term use of finasteride and minoxidil, considering switching to dutasteride and increasing minoxidil dosage. Suggestions included trying topical minoxidil and adding a topical antiandrogen, but avoiding RU58841.
The conversation is about a user's 17-month progress in treating hair loss using finasteride, minoxidil, occasional 0.5mm microneedling, and Nizoral. The user reports significant hairline recovery and aims to achieve a pre-hair loss hairline within the next 6 months.
A 17-year-old experienced significant hair loss after switching from topical to oral minoxidil and adding finasteride. The recommendation is to return to topical minoxidil and continue with finasteride or consider dutasteride.
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.
The user experienced a sudden and severe hair loss after 1.5 years of successful treatment with finasteride and minoxidil. They plan to check their thyroid and vitamin D levels as potential causes.
A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.
The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
A user experienced high estrogen levels after 10 months of taking 1mg oral finasteride but is happy with hair regrowth. They are considering switching to topical finasteride and are also taking DIM and Zinc supplements.
The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.
The conversation discusses whether using pyrilutamide would interfere with minoxidil's ability to regrow hair, considering pyrilutamide is seen as a maintenance drug that stops shedding, while minoxidil promotes hair growth but causes initial shedding.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
User is experiencing severe hair loss despite using finasteride for 15 months, losing 500 hairs a day and 50% density since June. Minoxidil with needling was ineffective, and RU58841 is too expensive and hard to obtain.
A female user in her mid-20s with androgenetic alopecia and suspected telogene effluvium who has been taking Dutasteride, Spironolactone, Minoxidil, Dermarolling, Ketoconazol shampoo, and Yaz contraception for her hair loss for the past 6 months. She had a small shed during this time that she believes to be stress related.
Missing a few days of oral minoxidil won't significantly affect progress, but may cause temporary increased shedding. Resume normal dosage once the delivery arrives without doubling up.
A user discusses their habit of analyzing others' hair due to their own hair thinning at 18. Another user mentions starting finasteride in 2010 and still having a full head of hair.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.
HairClone plans to start hair multiplication services in 2022. Users discuss various treatments like Minoxidil, finasteride, PRP, and hair cloning, expressing both hope and skepticism about the technology and its costs.
Hair loss discussion includes Minoxidil and regrowth. Regrowing hairs start light and curly, then become dark and thick; losing temporal peaks is normal.